José Bines

6.7k total citations · 2 hit papers
94 papers, 3.7k citations indexed

About

José Bines is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, José Bines has authored 94 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 44 papers in Cancer Research and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in José Bines's work include Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (38 papers) and Advanced Breast Cancer Therapies (31 papers). José Bines is often cited by papers focused on Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (38 papers) and Advanced Breast Cancer Therapies (31 papers). José Bines collaborates with scholars based in Brazil, United States and Switzerland. José Bines's co-authors include Melody Cobleigh, Denise M. Oleske, Martine Piccart, Evandro de Azambuja, Emma Clark, Aman U. Buzdar, Marion Procter, István Láng, Amal Arahmani and Richard D. Gelber and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

José Bines

85 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

2017 918 citations Gϋnter von Minckwitz, Marion Procter et al. profile →
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.

1996 593 citations José Bines et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
José Bines Brazil	22	2.7k	1.4k	1.0k	694	549	94	3.7k
T. Delozier France	30	3.3k 1.2×	1.7k 1.2×	987 1.0×	468 0.7×	568 1.0×	92	4.3k
Diana Crivellari Italy	37	3.3k 1.2×	2.1k 1.5×	1.2k 1.2×	681 1.0×	694 1.3×	152	4.9k
Tiffany A. Traina United States	30	2.4k 0.9×	1.6k 1.1×	1.4k 1.4×	698 1.0×	1.1k 2.0×	146	4.0k
Chikako Shimizu Japan	30	2.1k 0.8×	689 0.5×	837 0.8×	245 0.4×	1.0k 1.9×	180	3.7k
M. Namer France	29	2.4k 0.9×	1.4k 1.0×	982 1.0×	612 0.9×	562 1.0×	122	3.7k
M. Castiglione Switzerland	26	2.8k 1.0×	2.5k 1.8×	835 0.8×	879 1.3×	715 1.3×	48	5.0k
Shani Paluch–Shimon Israel	24	2.2k 0.8×	1.2k 0.8×	1.4k 1.4×	743 1.1×	529 1.0×	77	3.5k
Eduardo R. Pajon United States	15	1.9k 0.7×	1.8k 1.3×	445 0.4×	929 1.3×	407 0.7×	22	3.4k
Florence Dalenc France	33	2.6k 1.0×	1.3k 1.0×	1.6k 1.5×	385 0.6×	1.3k 2.4×	209	4.5k
Rosalba Torrisi Italy	35	2.4k 0.9×	1.9k 1.4×	671 0.7×	724 1.0×	1.0k 1.9×	130	4.2k

Countries citing papers authored by José Bines

Since Specialization

Citations

This map shows the geographic impact of José Bines's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Bines with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Bines more than expected).

Fields of papers citing papers by José Bines

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Bines. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Bines. The network helps show where José Bines may publish in the future.

Co-authorship network of co-authors of José Bines

This figure shows the co-authorship network connecting the top 25 collaborators of José Bines. A scholar is included among the top collaborators of José Bines based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Bines. José Bines is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Migowski, Arn, Ruffo Freitas‐Júnior, José Bines, et al.. (2025). Cracking the code: Pioneering early detection and management of breast cancer in the Brazilian public healthcare system. Dialogues in Health. 7. 100235–100235.

Loibl, S., Carolyn J. Henry, Giovanni Tomasello, et al.. (2025). LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up. ESMO Open. 10. 105112–105112. 1 indexed citations

Werutsky, Gustavo, Juliana Giacomazzi, Daniela Dornelles Rosa, et al.. (2024). The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation. Revista Brasileira Ginecologia e Obstetrícia. 46.

Assad, Daniele Xavier, Flávia Paes, André Mattar, et al.. (2024). Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study. JCO Global Oncology. 10(10). e2300484–e2300484.

Bines, José, et al.. (2024). Delphi technique for design and content validation by experts of a mobile app for self-care of breast cancer-related lymphedema. Journal of Cancer Survivorship.

Crocamo, Susanne, et al.. (2022). Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer. PubMed. 4. 8–8. 1 indexed citations

Barrios, Carlos H., Ruffo Freitas‐Júnior, Sandro José Martins, et al.. (2021). Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology. 7(7). 474–485. 5 indexed citations

Bines, José, Emma Clark, Claire Barton, et al.. (2021). Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer. 125(1). 38–47. 5 indexed citations

Alves, Gilda, et al.. (2020). Cell free DNA biology and its involvement in breast carcinogenesis. Advances in clinical chemistry. 97. 171–223. 11 indexed citations

10.

Luo, Yang, Wěi Li, Zefei Jiang, et al.. (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anti-Cancer Drugs. 30(8). 866–872. 3 indexed citations

11.

Kirschbrown, Whitney P., Matts Kågedal, Bei Wang, et al.. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology. 83(6). 1147–1158. 9 indexed citations

12.

Bines, José, Marion Procter, Eleonora Restuccia, et al.. (2019). Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer. 20(2). 174–181.e3. 4 indexed citations

13.

Reinert, Tomás, et al.. (2018). Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. Chinese Clinical Oncology. 7(3). 25–25. 24 indexed citations

14.

Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2015). A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical Breast Cancer. 16(1). 38–44. 19 indexed citations

15.

Bines, José, Helena Earl, Antônio C. Buzaid, & Everardo D. Saad. (2014). Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Annals of Oncology. 25(6). 1079–1085. 55 indexed citations

16.

Bines, José, et al.. (2014). Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Annals of Oncology. 25(4). 831–836. 38 indexed citations

17.

Liedke, Pedro Emanuel Rubini, Dianne M. Finkelstein, Jackie Szymonifka, et al.. (2013). Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study. Cancer Epidemiology Biomarkers & Prevention. 23(1). 126–133. 71 indexed citations

18.

Sherrill, Beth, Angelo Di Leo, Mayur M. Amonkar, et al.. (2010). Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion. 26(4). 767–775. 12 indexed citations

19.

Leo, Angelo Di, Henry Gómez, Zeba Aziz, et al.. (2008). Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology. 26(34). 5544–5552. 345 indexed citations

20.

Eniu, Alexandru, Robert W. Carlson, Nagi S. El Saghir, et al.. (2008). Guideline implementation for breast healthcare in low- and middle-Income countries: Treatment resource allocation. Cancer. 113(S8). 2269–2281. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact